Inmedix, Unlocking the Autonomic Nervous System (ANS) to Treat Autoimmune Disease, Including Rheumatoid Arthritis (RA), Announces Scientific Advisory Board

Seattle, WA- January 12th, 2016- Inmedix , the leader in heart rate variability (HRV) application as an informative diagnostic tool in autoimmune disease, beginning with the more than two million U.S. patients with rheumatoid arthritis (RA), today announced the members of their Scientific Advisory Board. The board will play a vital role in 2016 as the company continues work to receive FDA 510 (k) clearance of their ANS Neuroscan™ and initiate a study to apply for a historic first time FDA claim to accurately predict treatment outcome for patients with RA.

Click below to read the full press release.